Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 04, 2023, titled "Zydus receives final approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg".
Press Release Jul 04 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Oxcarbazepine Tablets in various strengths. The tablets are used to treat seizure disorders and will be manufactured in Baddi, Himachal Pradesh.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jul 03 2023
- Press Release Jun 28 2023
- Press Release Jun 19 2023
- Press Release Jun 13 2023
- Press Release Jun 10 2023
Later from Zydus Lifesciences
- Press Release Jul 07 2023
- Press Release Jul 27 2023
- Press Release Aug 03 2023
- Press Release Aug 11 2023
- Press Release Aug 17 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences